We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Companion Testing Sector Increased Significantly in 2013

By LabMedica International staff writers
Posted on 07 Sep 2014
Print article
A new report from the healthcare market research firm Kalorama Information (New York, NY, USA) details the growth of the companion diagnostics testing sector. The analysis presented in the report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers, and marketing managers.

The global companion diagnostic market is valued at about USD 1.2 billion for 2013. This is an increase of USD 50 million from 2011, indicating a rise of 12.5%.

Kalorama expects even more rapid revenue growth in this area of in vitro diagnostics (IVD) over the next five years, which has become a primary area of focus for developers and many companion diagnostics are now successfully marketed with several of them part of a routine diagnostic and treatment plan. The report provides product analysis for five broad areas of medical companion diagnostics and market information: cancer, cardiovascular and blood, metabolic, infection, and neurological.

Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can significantly improve outcomes of a medical treatment. It also decreases costs by identifying the patient population that will probably benefit from the therapy, and ruling out therapies not likely to be effective. This is particularly important when considering the cost of new cancer therapies.

Mary Ann Crandall, analyst for Kalorama Information, commented, “There had been a slow market uptake of companion diagnostics because companion tests lacked the US Food and Drug Association (FDA; Silver Spring, MD, USA) approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective, has made companion diagnostics important to the delivery of care.”

Related Links:

Kalorama Information
US Food and Drug Association


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.